» Articles » PMID: 23533009

Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2013 Mar 28
PMID 23533009
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Social cognition is described as the higher mental processes that are engaged while people store, process, and use social information to make sense of themselves and others. Aspects of social cognition include emotion perception, social cue interpretation, attribution style, and theory of mind, all of which appear disordered in schizophrenia. Such social cognitive deficits are believed to be important predictors of functional outcome in schizophrenia, therefore they may represent a crucial treatment target. Few studies have evaluated the influence of antipsychotic treatment on these deficits. The purpose of this review is to examine the relationship between antipsychotic treatment and social cognition, whether antipsychotics improve social cognitive function, and if so to explore differential medication effects. Comprehensive searches of PsycINFO and MEDLINE/PUBMED were conducted to identify relevant published manuscripts. Fifteen relevant papers published in English were found, describing original studies. On the basis of this review, we have drawn the following conclusions: first, the results do not engender optimism for the possibility that antipsychotic drugs can specifically facilitate social recovery. Second, the actions of antipsychotics on social cognition are inconclusive, due to lack of standardization across research groups, leading to inconsistencies between study designs, methods used, and medication dosages. Third, large-scale longitudinal investigations are needed to explore the unclear relationships between social cognition, symptoms, and functional outcome. Other non-pharmacological treatments focusing on training patients in the social cognitive areas may hold more promise.

Citing Articles

Social cognitive training among individuals with schizophrenia: Identifying responders to treatment.

Vaskinn A, Lovgren A, Andreassen O, Sundet K Schizophr Res Cogn. 2025; 40:100350.

PMID: 40028173 PMC: 11870262. DOI: 10.1016/j.scog.2025.100350.


International perspective on social cognition in schizophrenia: current stage and the next steps.

Corbera S, Kurtz M, Achim A, Agostoni G, Amado I, Assaf M Eur Psychiatry. 2025; 68(1):e9.

PMID: 39812093 PMC: 11795453. DOI: 10.1192/j.eurpsy.2024.1776.


Validation of behavioral measures of social cognition in individuals diagnosed with schizophrenia.

Rahamim N, Gilad R, Linkovski O, Bergman H, Avirame K, Foul Y Front Psychol. 2024; 15:1443145.

PMID: 39319067 PMC: 11420990. DOI: 10.3389/fpsyg.2024.1443145.


Combining transcranial magnetic stimulation with training to improve social cognition impairment in schizophrenia: a pilot randomized controlled trial.

Vergallito A, Gramano B, La Monica K, Giuliani L, Palumbo D, Gesi C Front Psychol. 2024; 15:1308971.

PMID: 38445059 PMC: 10912559. DOI: 10.3389/fpsyg.2024.1308971.


Effects of NMDA-receptor blockade by ketamine on mentalizing and its neural correlates in humans: a randomized control trial.

Wasserthal S, Lehmann M, Neumann C, Delis A, Philipsen A, Hurlemann R Sci Rep. 2023; 13(1):17184.

PMID: 37821513 PMC: 10567921. DOI: 10.1038/s41598-023-44443-6.


References
1.
Machado de Sousa J, Hallak J . Neurocognitive functioning and facial affect recognition in treatment-resistant schizophrenia treated with clozapine. Schizophr Res. 2008; 106(2-3):371-2. DOI: 10.1016/j.schres.2008.09.012. View

2.
Lewis S, Garver D . Treatment and diagnostic subtype in facial affect recognition in schizophrenia. J Psychiatr Res. 1995; 29(1):5-11. DOI: 10.1016/0022-3956(94)00033-n. View

3.
Sergi M, Green M, Widmark C, Reist C, Erhart S, Braff D . Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007; 164(10):1585-92. DOI: 10.1176/appi.ajp.2007.06091515. View

4.
Littrell K, Petty R, Hilligoss N, Kirshner C, Johnson C . Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine. Schizophr Res. 2004; 66(2-3):201-2. DOI: 10.1016/S0920-9964(03)00185-3. View

5.
Bigelow N, Paradiso S, Adolphs R, Moser D, Arndt S, Heberlein A . Perception of socially relevant stimuli in schizophrenia. Schizophr Res. 2006; 83(2-3):257-67. DOI: 10.1016/j.schres.2005.12.856. View